Additionally, our observations indicated that the expression levels of PSME3 can predict the response to immunotherapy with PDL1 and CTLA4 in gastric adenocarcinoma and breast cancer in mouse models (Figure 8B). The gene discussed is PSME3; the disease is gastric adenocarcinoma.